Citation Information :
Begum MR, Banu LA, Rahman RR, Dewan F, Rouf S. Use of Metformin in Clomiphene Citrate (CC) Resistant Polycystic Ovary Syndrome (PCOS). J South Asian Feder Obs Gynae 2009; 1 (1):1-9.
A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynaecol 2004;191;713-17.
Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986;293:355-59.
More data still needed on efficacy, safety of metformin for PCOS. Reuters Health Information 2002. Medscape Ob/Gyn and Women's Health 7 (2),2002.
Decreases in ovarian cytochrome P450c17 alpha activity and serum-free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23.
Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989;68:1027-32.
The insulinrelated ovarian regulatory system in health and disease. Endocr Rev 1999;20:535-82.
The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60: 1-17.
Diagnosing PCOS in women who menstruate regularly. Contemp Obstet Gynaecol 2003;53-64.
Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertil Steril 1979;32:641-45.
Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982;37: 168-74.
Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod 1996;11:2623-28.
Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.
Effect of metformin and glucose metabolism in mouse soleus muscle. Diabetes Metab 1986;12:212-18.
Insulin, androgens and obesity in women with and without polycystic ovary syndrome: A heterogenous group of disorders. Fertil Steril 1999;72: 32-40.
Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999;13:946-57.
Hyperinsulinemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin. Clinical Endocrinolgy (Oxford) 1993;38:219-22.
Role of obesity and insulin in the development of anovulation. In: Filicori M, Flamigni C, (Eds). Ovulation induction: Basic science and clinical advances. Amsterdam: Elsevier Science BV 1994;103-14.
Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62:904-10.
A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1991;72:83-89.
Decrease in ovarian cytochrome P450c 17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-23.
Defects in b-cell function in functional ovarian hyperandrogenism. J Clin Endrocrinol Metab. 1993;76:1241-47.
Distribution and characterisation of insulin and insulin-like growth factor-1 receptors in normal human ovary. J Clin Endocrinol Metab 1985;61:728-34.
Insulin resistance with Acanthosis nigricans: The role of obesity and androgen excess. Metabolism 1986;35:197-205.
Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41:1257-66.
Insulin infusion amplifies 17 alpha hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: Apparent relative impairment of 17, 20-lyase activity. J Clin Endocrinol Metab 1996;81:881-86.
Modulation by insulin of follicle stimulating hormone and luteinizing hormone actions in human granulose cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 1996;81:302-09.
The effects of growth factors and phorbol esters on steroid biosynthesis in isolated human theca interna and granulose-lutein cells in long-term culture. J Clin Endocrinol Metab 1994;79:106-12.
Relationship of androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women. J Clin Endocrinol Metab 1987;64:162-69.
Polycystic ovary syndrome: Treatment with insulin lowering medications. http://wwwivf.com .
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167-74.
Metformin. N Eng J Med 1996;334:574-79.
Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: A direct metformin effect on pancreatic beta cells. Diabetes 2000;49:735-40.
Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994;24:49-57.
Role of metformin accumulation in metformin associated lactic acidosis. Diabetes Care 1995;18:779-84.
Adverse reactions to iodinated contrast media. Eur Radiol 2001;11:1267-75.
Metformin and contrast media—a dangerous combination. Clin Radiol 1999;54:29-33.
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor –1, lipoprotein (a) and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997;46:454-57.
Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:524-30.
Can metformin reduce insulin resistance in polycystic ovary syndrome Ferti Steril 1996;65:946-49.
Lean women with polycystic ovary syndrome respond to insulin reduction with decrease in ovarian P450c 17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-79.
Menstrual cyclicity alter metformin therapy in polycystic ovary syndrome. Obstet Gynaecol 1997;90:392-95.
Metformin induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome. Metabolism 1999;48:511-19.
Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome: A randomized doubleblind, placebo controlled 6 month trial, followed by open longterm clinical evaluation. J Clin Endocrinol Metab 2000;85: 139-46.
Metfrormin inceases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75: 310-15.
The treatment of insulin resistance does not improve adrenal cytochrome p450c 17 alpha enzyme dysregulation in polycystic ovary syndrome. Eur J Endocrinol 1990;140:56-61.
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Eng J Med 1998;338:1876-80.
Clomiphene, metformin or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-66.
Use of metformin in polycystic ovary syndrome: A meta-analysis. Obstet Gynaecol 2008;111:959-68.
Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-22.
Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002;77:669-73.
Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch Gynecol Obstet 2001;265:124-27.
Drug insight: Insulin sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal. Nat Clin Pract Endocrinol Metab. 2008;4:272-83.
Metformin and body weight. Int J Obes (London). 2008;32:61-72.
Metformin and weight loss in obese with polycystic ovary syndrome: Comparison of doses. J Clin Endocrinol Metab 2005;90:4593-98.
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-74.
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:241-49.
Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is… J Clin Endocrinol Metab 2007;92:3399-3401.
Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:101-06.
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 1999;72:S12.
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate resistant polycystic ovarian syndrome: A prospective randomized trial. Hum Reprod 2002;17:289-94.
Insulin action on ovarian steroidogenesis are not modulated by metformin. Hum Reprod. 1993;8:1194-98.
Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril 2001;75:505-09.
Miscarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 1993;8:959-64.
Influence of serum Leutenizing become concentration on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988;297:1024-26.
Hypersecretion of Leutenizing hormone, infertility, and miscarriage. Lancet 1990;336:1141-44.
Recurrent early miscarriage and polycystic ovaries. BMJ 1988;297:1027-28.
Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod 1993;8:829-33.
Subfertility and risk of spontaneous abortion. Am J Public Health 2000;90:1452-54.
Influence of past reproductive performance on risk of spontaneous abortion. BMJ 1989;299:541-45.
An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of 500 consecutive cases. Hum Reprod 1994;9: 1328-32.
Recurrent miscarriage: Screening for polycystic ovaries and subsequent pregnancy outcome. Aust N Z J Obstet Gynaecol 1997;37:402-06.
Obesity is a risk factor for early pregnancy loss ater IVF or ICSI. Acta Obstet Gynaecol Scand 2000;79:43-48.
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study. Fertil Steril 2002;77: 520-25.
Plasminogen activator inhibitor activity (an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome). Metabolism 1999;48:1589-95.
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-74.
Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691-96.
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenimia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54.
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce firsttrimester spontaneous abortion (a pilot study). Fertil Steril 2001;75:46-52.
Diagnostic criteria for polycystic ovary syndrome (a rational approach). In: Dunaif A, Givens JR, Haseltine F, Merriam GR editor. Polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 1992;377-84.
The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989-93.
Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 2001;16:226-29.
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002;77:520-25.
Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril 2008;89:625-34.
Prevention of GDM by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome (PCOS). Journal of Obstetrical and Gynaecological Research. (In Press).
Polycystic ovaries in women with gestational diabetes. Obstet Gynecol 1998;92:13-16.
High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;84:1143-50.
The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin Endocrinol (Oxf). 2000;53:501-07.
Polycystic ovary disease. A risk factor for gestational diabetes? J Reprod Med 1995;40:312-16.
Association between polycystic ovary syndrome and glucose intolerance during pregnancy. J Matern Fetal Med 1997;6:303-07.
Endocrinometabolic features in women with polycystic ovary syndrome during pregnancy. Hum Reprod 1998;13:542-46.
Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Diabetologia 1999;94:194-97.
Carbohydrate and lipid metabolism in pregnancy (normal compared with gestational diabetes mellitus). Am J Clin Nutr. 2000;71(suppl):1256S-61S.
Metformin in management of pregnant insulin-independent diabetes. Diabetologia 1979;16:241-45.
Oral hypoglycaemics in the first trimester and foetal outcome. S Afr Med J 1984;65:635-37.
The management of non-insulindependent diabetes during pregnancy. Diabetes Res Clin Pract 1985;1:281-87.